首页 > 最新文献

THERAPEUTISCHE UMSCHAU最新文献

英文 中文
[Glucocorticoid-induced Osteoporosis; Epidemiology, Pathogenesis and Treatment].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.005
Anna Madrid, Catherine Lamm, Daniel Aeberli

Introduction: Glucocorticoid (GC) therapy has been shown to be associated with a dose-dependent significantly elevated risk of osteoporosis and fractures. It is estimated that about 3 % of the population are prescribed systemic GC on a daily basis, and approximately 30-50 % of patients treated with GC experience an osteoporotic fracture. Evidence has been mounting that inhaled, topical, and locally infiltrated GC also adversely affect bone mineral density. At the cellular level, GC have been shown to activate osteoclasts and inhibit the activity of osteoblasts and osteocytes, resulting in a loss of bone mass and a deterioration in bone quality, thereby increasing fracture risk. Patients prescribed a daily dosage of ≥ 5 mg of prednisone equivalents for a period of at least three months should undergo a bone density assessment and a fracture risk evaluation. Lifestyle modifications, including physical activity as well as calcium and vitamin D supplementation are recommended for all patients with GC therapy. In cases of a very high risk for fracture, the administration of osteoanabolic therapy followed by antiresorptive therapy is imperative. In patients with high fracture risk, antiresorptive therapy is recommended, whereas for those at moderate/low risk for fracture selective estrogen receptor modulators or oral bisphosphonates can be considered.

导言糖皮质激素(GC)治疗已被证明与骨质疏松症和骨折风险的剂量依赖性显著升高有关。据估计,约有 3% 的人每天服用全身性糖皮质激素,约有 30-50% 接受糖皮质激素治疗的患者会发生骨质疏松性骨折。越来越多的证据表明,吸入、局部和局部浸润的 GC 也会对骨矿物质密度产生不利影响。在细胞水平上,已证明 GC 可激活破骨细胞,抑制成骨细胞和骨细胞的活性,导致骨量损失和骨质恶化,从而增加骨折风险。每天服用≥ 5 毫克泼尼松当量的药物至少三个月的患者应接受骨密度评估和骨折风险评估。建议所有接受 GC 治疗的患者改变生活方式,包括进行体育锻炼以及补充钙和维生素 D。在骨折风险极高的情况下,必须先进行骨合成代谢治疗,然后再进行抗骨吸收治疗。对于骨折风险较高的患者,建议采用抗骨吸收疗法,而对于中度/低度骨折风险的患者,可以考虑选择性雌激素受体调节剂或口服双膦酸盐。
{"title":"[Glucocorticoid-induced Osteoporosis; Epidemiology, Pathogenesis and Treatment].","authors":"Anna Madrid, Catherine Lamm, Daniel Aeberli","doi":"10.23785/TU.2025.01.005","DOIUrl":"https://doi.org/10.23785/TU.2025.01.005","url":null,"abstract":"<p><strong>Introduction: </strong>Glucocorticoid (GC) therapy has been shown to be associated with a dose-dependent significantly elevated risk of osteoporosis and fractures. It is estimated that about 3 % of the population are prescribed systemic GC on a daily basis, and approximately 30-50 % of patients treated with GC experience an osteoporotic fracture. Evidence has been mounting that inhaled, topical, and locally infiltrated GC also adversely affect bone mineral density. At the cellular level, GC have been shown to activate osteoclasts and inhibit the activity of osteoblasts and osteocytes, resulting in a loss of bone mass and a deterioration in bone quality, thereby increasing fracture risk. Patients prescribed a daily dosage of ≥ 5 mg of prednisone equivalents for a period of at least three months should undergo a bone density assessment and a fracture risk evaluation. Lifestyle modifications, including physical activity as well as calcium and vitamin D supplementation are recommended for all patients with GC therapy. In cases of a very high risk for fracture, the administration of osteoanabolic therapy followed by antiresorptive therapy is imperative. In patients with high fracture risk, antiresorptive therapy is recommended, whereas for those at moderate/low risk for fracture selective estrogen receptor modulators or oral bisphosphonates can be considered.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"20-25"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Osteoporosis therapy - Update 2025, Part 2: Sequential osteoporosis therapy].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.007
Christian Meier, Judith Everts-Graber, Serge Ferrari

Introduction: Osteoporosis is a chronic disease that requires lifelong therapy management that includes both non-drug and drug-based approaches. The availability of various drugs for osteoporosis therapy, characterized by different mechanisms of action, has significantly changed treatment strategies in recent years. Due to the potential treatment risks associated with long-term monotherapy and the fact that the osteoanabolic therapies used in patients with a high fracture risk are time-limited, sequential treatment strategies are increasingly being used today. The aim of this review article is to present the significance of different treatment sequences in osteoporosis drug therapy.

{"title":"[Osteoporosis therapy - Update 2025, Part 2: Sequential osteoporosis therapy].","authors":"Christian Meier, Judith Everts-Graber, Serge Ferrari","doi":"10.23785/TU.2025.01.007","DOIUrl":"https://doi.org/10.23785/TU.2025.01.007","url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis is a chronic disease that requires lifelong therapy management that includes both non-drug and drug-based approaches. The availability of various drugs for osteoporosis therapy, characterized by different mechanisms of action, has significantly changed treatment strategies in recent years. Due to the potential treatment risks associated with long-term monotherapy and the fact that the osteoanabolic therapies used in patients with a high fracture risk are time-limited, sequential treatment strategies are increasingly being used today. The aim of this review article is to present the significance of different treatment sequences in osteoporosis drug therapy.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"32-34"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Risk of jaw osteonecrosis and atypical femoral fracture: how to inform patients with osteoporosis?]
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.008
Albrecht W Popp

Introduction: Amino-bisphosphonates (BP), such as zoledronate, alendronate, ibandronate or risedronate, and the antibody therapies with denosumab (DMAb) or romosozumab (ROMO) are highly effective therapies for reducing the risk of vertebral fractures and non-vertebral fractures in patients with osteoporosis. Generally very well tolerated, these antiresorptive therapies have an association with bone-specific adverse events such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). This association leads to uncertainty among patients and treating physicians as to how the benefit-risk should be assessed in individual cases. By providing concrete answers to specific questions in connection with these rare events, patients can be informed in a targeted manner.

{"title":"[Risk of jaw osteonecrosis and atypical femoral fracture: how to inform patients with osteoporosis?]","authors":"Albrecht W Popp","doi":"10.23785/TU.2025.01.008","DOIUrl":"https://doi.org/10.23785/TU.2025.01.008","url":null,"abstract":"<p><strong>Introduction: </strong>Amino-bisphosphonates (BP), such as zoledronate, alendronate, ibandronate or risedronate, and the antibody therapies with denosumab (DMAb) or romosozumab (ROMO) are highly effective therapies for reducing the risk of vertebral fractures and non-vertebral fractures in patients with osteoporosis. Generally very well tolerated, these antiresorptive therapies have an association with bone-specific adverse events such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). This association leads to uncertainty among patients and treating physicians as to how the benefit-risk should be assessed in individual cases. By providing concrete answers to specific questions in connection with these rare events, patients can be informed in a targeted manner.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"35-38"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Premenopausal osteoporosis].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.004
Elena Tsourdi

Introduction: Premenopausal osteoporosis is often overlooked because fragility fractures and low bone mass are uncommon in premenopausal women. The definition and diagnostic criteria for premenopausal osteoporosis are less well defined than for postmenopausal women. Diagnostic procedures should be initiated in premenopausal women with existing fragility fractures or diseases and drug therapies that cause bone loss. Recent studies have shown that lifestyle and dietary habits influence bone mass in the premenopausal phase. Bone mass can be improved by an adequate intake of calcium and vitamin D in combination with increased physical activity in premenopausal women with idiopathic osteoporosis. Secondary causes of osteoporosis should be corrected or treated if possible. In women with recurrent fractures or secondary causes that cannot be reversed, e.g. glucocorticoids or oncological treatments, pharmacological intervention with bisphosphonates or teriparatide (the latter not in patients with carcinomas) may be considered. Antiresorptive and osteoanabolic agents have been shown to effectively increase bone mass; however, no studies have been conducted to date with fractures as the primary endpoint.

{"title":"[Premenopausal osteoporosis].","authors":"Elena Tsourdi","doi":"10.23785/TU.2025.01.004","DOIUrl":"https://doi.org/10.23785/TU.2025.01.004","url":null,"abstract":"<p><strong>Introduction: </strong>Premenopausal osteoporosis is often overlooked because fragility fractures and low bone mass are uncommon in premenopausal women. The definition and diagnostic criteria for premenopausal osteoporosis are less well defined than for postmenopausal women. Diagnostic procedures should be initiated in premenopausal women with existing fragility fractures or diseases and drug therapies that cause bone loss. Recent studies have shown that lifestyle and dietary habits influence bone mass in the premenopausal phase. Bone mass can be improved by an adequate intake of calcium and vitamin D in combination with increased physical activity in premenopausal women with idiopathic osteoporosis. Secondary causes of osteoporosis should be corrected or treated if possible. In women with recurrent fractures or secondary causes that cannot be reversed, e.g. glucocorticoids or oncological treatments, pharmacological intervention with bisphosphonates or teriparatide (the latter not in patients with carcinomas) may be considered. Antiresorptive and osteoanabolic agents have been shown to effectively increase bone mass; however, no studies have been conducted to date with fractures as the primary endpoint.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"13-19"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The importance of bone remodelling parameters in the management of osteoporosis].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.002
Devran Topyürek, Christian Meier, Marius E Kränzlin

Introduction: Bone is continuously remodelled. Bone turnover markers reflect the activity of osteoblasts and osteoclasts during remodelling. Collagen synthesis by osteoblasts is reflected by the formation of bone-specific alkaline phosphatase (BALP), osteocalcin (OC) and procollagen N-propeptides (P1NP). During bone resorption, fragments of collagen (N- and C-terminal telopeptides, pyridinolines) and tartrate-resistant acid phosphatase (TRACP) are released. These markers enable a dynamic assessment of bone remodelling. P1NP is recommended as a reference marker for bone formation and ßCTX for bone resorption. Using and, above all, interpreting the results of bone turnover markers, it is impor-tant to take into account the various sources of variability of these markers, such as diurnal rhythm, day-to-day fluctuations, food intake and also the stability of the marker after blood sampling. The most important area for the clinical use of bone turnover markers is the monitoring of antiresorptive or anabolic treatments of osteoporosis. A short-term decrease in bone turnover during antiresorptive therapy correlates with an increase in bone density after 1-2 years and a decrease in fracture risk. The bone formation markers, especially P1NP, correlate with the increase in bone mineral density on anabolic treatment.

简介骨骼不断重塑。骨转换标志物反映了重塑过程中成骨细胞和破骨细胞的活动。骨特异性碱性磷酸酶(BALP)、骨钙素(OC)和原胶原 N-肽(P1NP)的形成反映了成骨细胞的胶原合成。在骨吸收过程中,胶原蛋白片段(N 端和 C 端端肽、吡啶啉)和抗酒石酸磷酸酶(TRACP)会被释放出来。这些标记物可对骨重塑进行动态评估。建议将 P1NP 作为骨形成的参考标记,将 ßCTX 作为骨吸收的参考标记。在使用和解释骨转换标记物的结果时,必须考虑到这些标记物的各种变化来源,如昼夜节律、日常波动、食物摄入量以及采血后标记物的稳定性。骨转换标志物最重要的临床应用领域是监测骨质疏松症的抗吸收或合成代谢治疗。在抗骨吸收治疗过程中,骨转换率的短期下降与 1-2 年后骨密度的增加和骨折风险的降低相关。骨形成标志物,尤其是 P1NP,与同化治疗中骨矿物质密度的增加相关。
{"title":"[The importance of bone remodelling parameters in the management of osteoporosis].","authors":"Devran Topyürek, Christian Meier, Marius E Kränzlin","doi":"10.23785/TU.2025.01.002","DOIUrl":"https://doi.org/10.23785/TU.2025.01.002","url":null,"abstract":"<p><strong>Introduction: </strong>Bone is continuously remodelled. Bone turnover markers reflect the activity of osteoblasts and osteoclasts during remodelling. Collagen synthesis by osteoblasts is reflected by the formation of bone-specific alkaline phosphatase (BALP), osteocalcin (OC) and procollagen N-propeptides (P1NP). During bone resorption, fragments of collagen (N- and C-terminal telopeptides, pyridinolines) and tartrate-resistant acid phosphatase (TRACP) are released. These markers enable a dynamic assessment of bone remodelling. P1NP is recommended as a reference marker for bone formation and ßCTX for bone resorption. Using and, above all, interpreting the results of bone turnover markers, it is impor-tant to take into account the various sources of variability of these markers, such as diurnal rhythm, day-to-day fluctuations, food intake and also the stability of the marker after blood sampling. The most important area for the clinical use of bone turnover markers is the monitoring of antiresorptive or anabolic treatments of osteoporosis. A short-term decrease in bone turnover during antiresorptive therapy correlates with an increase in bone density after 1-2 years and a decrease in fracture risk. The bone formation markers, especially P1NP, correlate with the increase in bone mineral density on anabolic treatment.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"2-9"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Vitamin D - What is the current advice?]
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.003
Heike A Bischoff-Ferrari

Introduction: We have gained new insights into vitamin D. High quality studies of over 36,000 people have shown that daily vitamin D supplementation of 800 IU reduces the risk of hip fracture and falling in older adults with vitamin D deficiency and existing falling risk. We have also learnt that vitamin D supplementation in healthy middle-aged and elderly people without vitamin D deficiency and without osteoporosis offers no additional protection. Also, large intermittent bolus doses of vitamin D either show no protection against fractures or even lead to an increase in fracture risk and fall risk in vulnerable elderly people and are therefore obsolete. In recent years, however, large randomised studies on daily vitamin D supplementation with 2000 IU in healthy people without vitamin D deficiency at the age of 50 (VITAL) and at the age of 70 (DO-HEALTH) have shown a benefit on the immune system in terms of reducing advanced cancers, cancer mortality and autoimmune diseases.

{"title":"[Vitamin D - What is the current advice?]","authors":"Heike A Bischoff-Ferrari","doi":"10.23785/TU.2025.01.003","DOIUrl":"https://doi.org/10.23785/TU.2025.01.003","url":null,"abstract":"<p><strong>Introduction: </strong>We have gained new insights into vitamin D. High quality studies of over 36,000 people have shown that daily vitamin D supplementation of 800 IU reduces the risk of hip fracture and falling in older adults with vitamin D deficiency and existing falling risk. We have also learnt that vitamin D supplementation in healthy middle-aged and elderly people without vitamin D deficiency and without osteoporosis offers no additional protection. Also, large intermittent bolus doses of vitamin D either show no protection against fractures or even lead to an increase in fracture risk and fall risk in vulnerable elderly people and are therefore obsolete. In recent years, however, large randomised studies on daily vitamin D supplementation with 2000 IU in healthy people without vitamin D deficiency at the age of 50 (VITAL) and at the age of 70 (DO-HEALTH) have shown a benefit on the immune system in terms of reducing advanced cancers, cancer mortality and autoimmune diseases.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"10-12"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Osteoporosis therapy - Update 2025, Part 1: Antiresorptive and osteoanabolic therapy options].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.006
Serge Ferrari, Judith Everts-Graber, Christian Meier

Introduction: Osteoporosis is a chronic disease that requires lifelong therapy management that includes both preventive measures and pharmacological approaches. The medical treatment of osteoporosis has changed considerably in recent years, particularly due to the availability of new substances, especially osteoanabolic drugs. The wide range of antiresorptive (estrogens, raloxifene, bisphosphonates, denosumab) and osteoanabolic (teriparatide, romosozumab) preparations for the treatment of osteoporosis makes it possible today to use them in a targeted manner based on the individual fracture risk. The uncertainty in their use can contribute to the underuse and lack of treatment of patients with osteoporosis, especially patients with a high fracture risk. This review article will summarize the mechanisms of action and clinical efficacy of antiresorptive and, in particular, anabolic agents and discuss its value for osteoporosis therapy.

简介骨质疏松症是一种慢性疾病,需要终身治疗管理,包括预防措施和药物治疗方法。近年来,骨质疏松症的药物治疗发生了很大变化,这主要归功于新药物的出现,尤其是骨合成代谢药物。用于治疗骨质疏松症的抗骨吸收药物(雌激素、雷洛昔芬、双膦酸盐、地诺单抗)和促骨合成药物(特立帕肽、罗莫单抗)种类繁多,如今可以根据个人骨折风险有针对性地使用这些药物。这些制剂使用的不确定性可能导致骨质疏松症患者,尤其是骨折风险较高的患者使用不足或缺乏治疗。这篇综述文章将总结抗骨吸收剂,尤其是同化制剂的作用机制和临床疗效,并讨论其在骨质疏松症治疗中的价值。
{"title":"[Osteoporosis therapy - Update 2025, Part 1: Antiresorptive and osteoanabolic therapy options].","authors":"Serge Ferrari, Judith Everts-Graber, Christian Meier","doi":"10.23785/TU.2025.01.006","DOIUrl":"https://doi.org/10.23785/TU.2025.01.006","url":null,"abstract":"<p><strong>Introduction: </strong>Osteoporosis is a chronic disease that requires lifelong therapy management that includes both preventive measures and pharmacological approaches. The medical treatment of osteoporosis has changed considerably in recent years, particularly due to the availability of new substances, especially osteoanabolic drugs. The wide range of antiresorptive (estrogens, raloxifene, bisphosphonates, denosumab) and osteoanabolic (teriparatide, romosozumab) preparations for the treatment of osteoporosis makes it possible today to use them in a targeted manner based on the individual fracture risk. The uncertainty in their use can contribute to the underuse and lack of treatment of patients with osteoporosis, especially patients with a high fracture risk. This review article will summarize the mechanisms of action and clinical efficacy of antiresorptive and, in particular, anabolic agents and discuss its value for osteoporosis therapy.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"26-31"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Introduction: Osteoporosis].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2025-02-01 DOI: 10.23785/TU.2025.01.001
Christian Meier

Introduction:

介绍:
{"title":"[Introduction: Osteoporosis].","authors":"Christian Meier","doi":"10.23785/TU.2025.01.001","DOIUrl":"https://doi.org/10.23785/TU.2025.01.001","url":null,"abstract":"<p><strong>Introduction: </strong></p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 1","pages":"1"},"PeriodicalIF":0.2,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Metatarsalgia]. [跖骨痛]
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-01 DOI: 10.23785/TU.2024.07.002
Fabienne Inglin, Markus Knupp

Introduction: Metatarsalgia is a generic term for complaints in the forefoot and the metatarsophalangeal joints II-IV. However, it does not describe a specific clinical picture but rather a complex of symptoms, which can have different causes. There are mechanical causes, e.g. due congenital or acquired malformations of the foot. Splayfeet with a bunion malformation combined with transfer a common cause. Other examples include brachimetatarsalgia or an instability of the first ray. Other, non-mechanical causes are Morton's neuroma, stress fractures, systemic diseases (rheumatoid arthritis, gout) or infections and aseptic necrosis. Metatarsalgia is described as stress-dependent pain in the ball of the forefoot, which often has a burning or stabbing character. Sometimes a foreign body feeling is reported, as if one were walking on a «pebble». Wearing tight and hard shoes further provokes the symptoms. The therapy depends on the causes and should initially cover conservative options. This includes wearing proper shoes, foot gymnastic/stretching exercise, orthopedic insoles or even orthopedic shoes. Surgical options comprise of Morton's neuroma removal, deformity correction and ligament reconstruction.

{"title":"[Metatarsalgia].","authors":"Fabienne Inglin, Markus Knupp","doi":"10.23785/TU.2024.07.002","DOIUrl":"https://doi.org/10.23785/TU.2024.07.002","url":null,"abstract":"<p><strong>Introduction: </strong>Metatarsalgia is a generic term for complaints in the forefoot and the metatarsophalangeal joints II-IV. However, it does not describe a specific clinical picture but rather a complex of symptoms, which can have different causes. There are mechanical causes, e.g. due congenital or acquired malformations of the foot. Splayfeet with a bunion malformation combined with transfer a common cause. Other examples include brachimetatarsalgia or an instability of the first ray. Other, non-mechanical causes are Morton's neuroma, stress fractures, systemic diseases (rheumatoid arthritis, gout) or infections and aseptic necrosis. Metatarsalgia is described as stress-dependent pain in the ball of the forefoot, which often has a burning or stabbing character. Sometimes a foreign body feeling is reported, as if one were walking on a «pebble». Wearing tight and hard shoes further provokes the symptoms. The therapy depends on the causes and should initially cover conservative options. This includes wearing proper shoes, foot gymnastic/stretching exercise, orthopedic insoles or even orthopedic shoes. Surgical options comprise of Morton's neuroma removal, deformity correction and ligament reconstruction.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 7","pages":"240-244"},"PeriodicalIF":0.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Osteochondral lesions of the talus].
IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-12-01 DOI: 10.23785/TU.2024.07.005
Doria Juric, Nicola Krähenbühl

Introduction: The talus has a comparatively high occurrence of osteochondral lesions (OCL), largely due to its unique anatomic characteristics. These lesions can occur post-traumatic or primary. Patients often present with non-specific symptoms, making a thorough clinical examination essential. This examination should include assessing hindfoot alignment, performing antero-lateral and antero-medial palpation with the ankle joint slightly plantar-flexed and evaluating stability. Beyond standard X-ray examinations, additional imaging modalities such as magnetic resonance imaging (MRI) and arthro-computed tomography (CT) are valuable diagnostic tools. Surgical intervention is recommended for symp-tomatic patients with unstable OCL. Besides cartilage reconstructive procedures, options like fusion or prosthetic treatments are available for managing recurring pain.

{"title":"[Osteochondral lesions of the talus].","authors":"Doria Juric, Nicola Krähenbühl","doi":"10.23785/TU.2024.07.005","DOIUrl":"https://doi.org/10.23785/TU.2024.07.005","url":null,"abstract":"<p><strong>Introduction: </strong>The talus has a comparatively high occurrence of osteochondral lesions (OCL), largely due to its unique anatomic characteristics. These lesions can occur post-traumatic or primary. Patients often present with non-specific symptoms, making a thorough clinical examination essential. This examination should include assessing hindfoot alignment, performing antero-lateral and antero-medial palpation with the ankle joint slightly plantar-flexed and evaluating stability. Beyond standard X-ray examinations, additional imaging modalities such as magnetic resonance imaging (MRI) and arthro-computed tomography (CT) are valuable diagnostic tools. Surgical intervention is recommended for symp-tomatic patients with unstable OCL. Besides cartilage reconstructive procedures, options like fusion or prosthetic treatments are available for managing recurring pain.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"81 7","pages":"254-257"},"PeriodicalIF":0.2,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
THERAPEUTISCHE UMSCHAU
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1